Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older

Abstract Introduction Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF...

Full description

Bibliographic Details
Published in:	Infectious Diseases and Therapy
Main Authors:	Kosaku Komiya, Yoko Hirano, Kazumasa Kamei, Asuka Yoshida, Junko Morii, Ryohei Kobayashi, Reiko Sato
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-07-01
Subjects:	Cost-effectiveness Japan Older adults Respiratory syncytial virus RSV RSVpreF
Online Access:	https://doi.org/10.1007/s40121-025-01177-4

Similar Items

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
by: Michaela Höck, et al.
Published: (2025-10-01)

Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain
by: Javier Álvarez Aldean, et al.
Published: (2024-05-01)

Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
by: José Luis Huerta, et al.
Published: (2025-01-01)

Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States
by: Elizabeth M. La, et al.
Published: (2024-12-01)

Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin American countries
by: Ru Han, et al.
Published: (2025-12-01)

Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia
by: Ru Han, et al.
Published: (2025-12-01)

Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
by: Kumar Ilangovan, et al.
Published: (2025-08-01)

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
by: George Gourzoulidis, et al.
Published: (2024-10-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
by: Natalia Castillo Almeida, et al.
Published: (2025-03-01)

Public health impact of adjuvanted RSVPreF3 vaccine in older adults: a modeling study in nine countries in Middle East and North Africa
by: Evelina Zimovetz, et al.
Published: (2025-12-01)

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
by: Naruhiko Ishiwada, et al.
Published: (2024-06-01)

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
by: Daniel Molnar, et al.
Published: (2024-03-01)

RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023–2025 vaccination seasons
by: Elizabeth M. La, et al.
Published: (2025-12-01)

[Complementary Strategy of RSVpreF Vaccination/Nirsevimab versus Nirsevimab Alone for the Prevention of RSV Infection in Infants in Italy: A Cost-Minimization Analysis]
by: Giorgio Lorenzo Colombo, et al.
Published: (2025-07-01)

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
by: Bryony Treston, et al.
Published: (2024-12-01)

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01)

Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
by: Ahuva Averin, et al.
Published: (2025-12-01)

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material
by: Archana Jastorff, et al.
Published: (2024-12-01)

Respiratory syncytial virus immunization in children: The old, the new and what’s just around the corner
by: Bosco A. Paes, et al.
Published: (2025-12-01)

Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits
by: Jun Zhou, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
by: Akiko Mizukami, et al.
Published: (2024-12-01)

Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany
by: Maria Waize, et al.
Published: (2025-12-01)

Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina
by: Lucila Rey-Ares, et al.
Published: (2024-10-01)

RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy
by: Greg J. Marchand, et al.
Published: (2024-11-01)

Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States
by: Ahuva Averin, et al.
Published: (2025-12-01)

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65
by: Robert Buynak, et al.
Published: (2024-06-01)

Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada
by: Samara Bugden, et al.
Published: (2025-02-01)

Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus
by: Mostafa Zayed, et al.
Published: (2025-12-01)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life
by: Tessa Hosman, et al.
Published: (2024-12-01)

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment
by: Barbara Polistena, et al.
Published: (2025-07-01)

The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis
by: Daisuke Kurai, et al.
Published: (2024-12-01)

Respiratory syncytial virus vaccination among US adults aged ≥60 years
by: Xiaozhen Geng, et al.
Published: (2024-12-01)

Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
by: Pius I. Babawale, et al.
Published: (2025-01-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity
by: Anna Condemi, et al.
Published: (2025-07-01)

Enhanced safety surveillance of the adjuvanted respiratory syncytial virus vaccine among Italian older adults
by: Alexander Domnich, et al.
Published: (2025-06-01)

Mutation of Respiratory Syncytial Virus G Protein’s CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells
by: Binh Ha, et al.
Published: (2019-07-01)

RSV disease in infants and young children: Can we see a brighter future?
by: Eugenio Baraldi, et al.
Published: (2022-11-01)

Burden and Economic Impact of Respiratory Viral Infections in Adults Aged 60 and Older: A Focus on RSV
by: Adrián Peláez, et al.
Published: (2025-01-01)